Affiliation:
1. Registrar, Eye Dept., BIRDEM Hospital.
2. Assistant Professor, Sheikh Fajilatunnesa Mujib Eye Hospital, and Training Institute.
Abstract
Objective: To compare the efcacy and safety between laser therapy and anti-vascular endothelial growth factor (VEGF) agents for aggressive
retinopathy of prematurity (A-ROP). Acomparative study for laser, anti VEGF with laser and anti-VEGF mono therapy forPatients and methods:
A-ROP treatment. Study period was 2016 to 2020 at BIRDEM General Hospital. We included fteen A-ROP babies with thirty eyes. Ten eyes
treated with laser, ten eyes treated with anti-VEGF with laser and ten eyes treated with anti-VEGF. We used Bevacizumab as anti-VEGF. We
compared efcacy, safety, complication, retreatment between these three groups. Complication incidences were signicantly higher inResult:
laser therapy group. 20% of infants' needs retreatments with laser therapy more than two sessions. In anti-VEGF and laser therapy group, 6.7% of
infants need retreatment and in anti-VEGF group-1 3.3% infants need retreatment. P-value was 0.005 which is signicant. Development of myopia
is signicantly higher in laser therapy group (Group-3). About 100% infants' developed myopia. In Group-2 30% infants' developed myopia. In
Group-1 no infants developed myopia. P-value was highly signicant 0.01. This analysis outcome indicates anti-VEGF agents are asConclusion:
effective as laser treatment and safer than laser. The degree of myopia in A-ROP in laser group is higher than anti-VEGF mono therapy group. The
decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential
benet for patients treated with Intravitreal Bevacizumab (IVB).
Reference31 articles.
1. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123(7):991-9.
2. Sanghi G, Dogra MR, Katoch D, Gupta A. Aggressive posterior retinopathy of prematurity: risk factors for retinal detachment despite confluent laser photocoagulation. Am J Ophthalmol. 2013;155(1):159-64.
3. Shah PK, Ramakrishnan M, Sadat B, Bachu S, Narendran V, Kalpana N. Long term refractive and structural outcome following laser treatment for zone 1 aggressive posterior retinopathy of prematurity. Oman J Ophthalmol. 2014;7(3):116-9.
4. Gopal L, Sharma T, Ramachandran S, Shanmugasundaram R, Asha V. Retinopathy of prematurity: a study. Ind J Ophthal 1995; 43:59–61.
5. Varughese S, Jain S, Gupta N, Singh S, Tyagi V, Puliyel JM. Magnitude of the problem of retinopathy of prematurity. Experience in a large maternity unit with a medium size level-3 nursery. Ind J Ophthalmol 2001; 49:187–188.